Literature DB >> 28857507

Innovation of clinical trials in China: Commentary on the publication of "CONSORT extension for Chinese herbal medicine formulas 2017: Recommendations, explanation, and elaboration".

Taixiang Wu1, Zhaoxiang Bian2, Hongcai Shang3, Youping Li1.   

Abstract

Entities:  

Keywords:  CONSORT; Chinese herbal medicine formulas; checklist; clinical trial; data sharing; reporting guideline

Mesh：

Substances：

Year:  2017        PMID： 28857507     DOI： 10.1111/jebm.12268

Source DB:  PubMed          Journal:  J Evid Based Med        ISSN： 1756-5391


× No keyword cloud information.
  3 in total

1.  Using the RIGHT statement to evaluate the reporting quality of clinical practice guidelines in traditional Chinese medicine.

Authors:  Xia Yun; Chen Yaolong; Zeng Zhao; Zhou Qi; Wang Yangyang; Xie Runshen; Xie Xiuli; Li Hui
Journal:  PLoS One       Date:  2018-11-16       Impact factor: 3.240

2.  Efficacy of Guizhi Fuling Wan for primary dysmenorrhea: protocol for a randomized controlled trial.

Authors:  Yun Du; Yatong Li; Xianyun Fu; Chenjie Li; Luo Yanan
Journal:  Trials       Date:  2021-12-18       Impact factor: 2.728

3.  Quality of randomized controlled trials of new generation antidepressants and antipsychotics identified in the China National Knowledge Infrastructure (CNKI): a literature and telephone interview study.

Authors:  Zheng Tong; Fangzhou Li; Yusuke Ogawa; Norio Watanabe; Toshi A Furukawa
Journal:  BMC Med Res Methodol       Date:  2018-09-24       Impact factor: 4.615
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.